The estimated Net Worth of Jr. Michael Conick Hanley is at least $435 Mille dollars as of 8 June 2022. Jr Hanley owns over 28,200 units of Aeglea BioTherapeutics Inc stock worth over $434,762 and over the last 5 years Jr sold AGLE stock worth over $0.
Jr has made over 1 trades of the Aeglea BioTherapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Jr bought 28,200 units of AGLE stock worth $20,022 on 8 June 2022.
The largest trade Jr's ever made was buying 28,200 units of Aeglea BioTherapeutics Inc stock on 8 June 2022 worth over $20,022. On average, Jr trades about 4,029 units every 0 days since 2019. As of 8 June 2022 Jr still owns at least 36,200 units of Aeglea BioTherapeutics Inc stock.
You can see the complete history of Jr Hanley stock trades at the bottom of the page.
Jr's mailing address filed with the SEC is C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN, TX, 78746.
Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... e Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include: